Is HRT justified for symptom management in women at higher risk of developing breast cancer? (Q36645276)

15 August 2017

1 reference

title

Is HRT justified for symptom management in women at higher risk of developing breast cancer? (English)

1 reference

Hormone Replacement Therapy

15 August 2017

1 reference

Rippy L

1

1 reference

PubMed ID

17085372

15 August 2017

Marsden J

series ordinal

2

1 reference

15 August 2017

1 December 2006

1 reference

15 August 2017

1 reference

15 August 2017

9

1 reference

15 August 2017

6

1 reference

15 August 2017

404-415

1 reference

Epidemiology of breast cancer.

15 August 2017

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Breast cancer and hormone-replacement therapy in the Million Women Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

The impact of clinical trials on the use of hormone replacement therapy. A population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Treatment of menopausal symptoms: what shall we do now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

HABITS (hormonal replacement therapy after breast cancer--is it safe?), a randomised comparison: trial stopped

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Menopausal hormone therapy after breast cancer: the Stockholm randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

The million women study: a critique

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Endogenous sex hormone levels and mammographic density among postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Effects of estrogen and estrogen-progestin on mammographic parenchymal density. Postmenopausal Estrogen/Progestin Interventions (PEPI) Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Effects of different types of hormone replacement therapy on mammographic density

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Short-term cessation of hormone replacement therapy and improvement of mammographic specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Influence of personal characteristics of individual women on sensitivity and specificity of mammography in the Million Women Study: cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Use of the levonorgestrel-releasing intrauterine system and breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Digitized assessment of mammographic breast density in patients who received low-dose intrauterine levonorgestrel in continuous combination with oral estradiol valerate: a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Impact of menopausal hormone-replacement therapy on clinical and laboratory characteristics of breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Progestogens and breast cancer risk: the role of hormonal contraceptives and hormone replacement therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Inherited predisposition and breast cancer: modifiers of BRCA1/2-associated breast cancer risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

21 January 2018

Benign breast disorders

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Effects of tamoxifen on benign breast disease in women at high risk for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Biopsy confirmed benign breast disease, postmenopausal use of exogenous female hormones, and breast carcinoma risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Ipsilateral breast tumor recurrence following breast-conserving surgery for early-stage invasive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Prognostic impact of the early detection of metachronous contralateral breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Prevalence and treatment of menopausal symptoms among breast cancer survivors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Sexual functioning in long-term breast cancer survivors treated with adjuvant chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Side Effects of Adjuvant Endocrine Treatment in Premenopausal Breast Cancer Patients: A Prospective Randomized Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Acceptance of adjuvant therapy and quality of life issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Caution: Vaginal estradiol appears to be contraindicated in postmenopausal women on adjuvant aromatase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

The effect of tibolone in postmenopausal women receiving tamoxifen after surgery for breast cancer: a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

Effect of Short-Term Hormone Replacement Therapy on Breast Cancer Risk Reduction After Bilateral Prophylactic Oophorectomy in BRCA1 and BRCA2 Mutation Carriers: The PROSE Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F13697130601022367

10.1080/13697130601022367

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference

PubMed ID

17085372